Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Finanšu pārskati |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2014-02-28 18:32:10 |
Versijas komentārs | |
Teksts |
Olaine, February 28, 2014ī
Last year “Olainfarm”
Increased Sales to 78 Million Euro
Consolidated profit and
loss account of AS „Olainfarm” for 2013 shows that the company has
reached a new sales record of 54.8 million lats (78 million
euro). This represents an increase by 4% compared to 2012,
when sales of AS “Olainfarm” were 52.9 million lats (75.3 million
euro).
After tax profit of the company in 2013 was 8.9 million lats (12.6
million euro), which is a reduction by 8% compared to 2012, when
the net profit was 0.8 million lats (13.9 million euro).
“This year our investments will be particularly strongly focused on
infrastructure and capacities of „Olainfarm”. Creation of new
production unit for nitrofuranes is the biggest of such
investments. Since last year we acquired more than 70% shares
in Silvanols, a leading Latvian producer of food supplements, we
intend to use our experience in promotion and marketing in CIS
countries to help Silvanols strengthen its position there. We
will continue working at improving our portfolio, entering new
markets and co-marketing. Development of chain of „Latvijas
aptieka” is also among our priorities, although number of
pharmacies this year will increase at a slower pace than during
previous years,” says Valerijs Maligins, Chairman of the Board of
AS "Olainfarm".
During 2013 sales to all key markets of AS „Olainfarm” continued
growing, except Ukraine, where due to the above mentioned extra
shipments of 2012 they shrank by 45%. The biggest sales
increases were achieved in The Netherlands, where products for
WHO’s anti-tuberculosis products are being sent. Sales there
have increased by 351%. Significant sales increase has also
been achieved in Spain (sales grew by 202%), Belarus (sales grew by
48%) and Uzbekistan (sales grew by 42%). Major sales markets
of AS “OlainFarm” in 2013 were Russia, Latvia, Ukraine, Belarus,
Kazakhstan and the UK.
During 2013 37 products have been registered in 7 different
countries, including the marketing partnership products.
Registration processes have been started also in Turkey, Mongolia,
Mexico and Kosovo.
In December 2013 Management Board of AS “OlainFarm” adjusted
previously set profit and sales guidance. According to them the
sales of the Concern in 2013 were planned to be 52.8 million lats
(75.1 million euro) while the net profit guidance was 8.8 million
lats (12.5 million euro). According to this unaudited report
the sales guidance has been outperformed by 3.8%, while profit
guidance was outperformed by 0.8%.
A/s OlainFarm is one of the
biggest pharmaceutical companies in Latvia with 40 years of
experience in production of medication and chemical and
pharmaceutical products. A basic principle of company's operations
is to produce reliable and effective top quality products for
Latvia and the rest of the world. Products made by the Group are
being exported to more than 30 countries of the world, including
the Baltics, Russia, other CIS, Europe, Asia, North America and
Australia. Information
prepared by:
|
Pielikumi |